I will like to see this protocol for pivotal very soon , if

New Post Public Reply Private Reply Replies (1) Message Board
misiu143
221
I will like to see this protocol for pivotal very soon , if they still have higher efficacy with longer overlap treatment with HAART , and if they will want to conduct this way our pivotal than they could only use patients started from the beginning this way , I know couple of weeks ago it was 22..,

Maybe this will depend how efficacy will look after this 10 weeks , and decision will be done then.,

Hopefully BLA part one will be submitted very soon and soon after we will know about pivotal ..
I only know that any time I had conversation with Dr NP he said how good / positive conversations they having with FDA about mono/pivotal ,,

And in few presentations he used words , induction part and maintenance part of the study .,
If that true , study will not take much longer than 30 weeks , probably will be done at the time when combo will be approved , and they will just ask for label extension at this time for mono .
I also think that FDA will require them to have much less patients than in investigational phase 3.

This is how I see things progressing .





CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Gaby Natale to Inspire at Procter & Gamble's LatinOvation

Updated Category News Views 189

Gaby Natale to Motivate at Procter & Gamble's LatinOvation Gaby Natale, a celebrated triple Emmy award-winning journalist and bestselling author, is poised to deliver the impactful closing keynote at Procter & Gamble's annual LatinOvation event. This year, the gathering continues to honor the substantial contributions from the Hispanic community, rallying around the theme...

Continue Reading
GitLab's Market Resilience and Adjustments in Earnings Outlook

Updated Category News Views 124

GitLab's Steady Growth Amid Price Forecast Adjustments In recent developments, analyst Pinjalim Bora from JP Morgan has reiterated a Neutral rating on GitLab Inc. (NASDAQ: GTLB), adjusting the price forecast from $65 down to $62. Quarterly Performance Shines GitLab’s recent quarterly earnings report revealed surprising strength, with the company posting earnings of 33...

Continue Reading
Understanding Recent Trading Trends for Exxon Mobil Options

Updated Category News Views 73

Insights into Exxon Mobil Options Trading Recent analysis highlights a bullish trend in Exxon Mobil's trading activity. Our examination of the stock, identified by the symbol XOM, has uncovered significant patterns in the options market. Our investigation into the history of options trading shows that 53% of traders are leaning towards a bullish outlook, while 33% have a...

Continue Reading
Ming Tsai Launches Exciting New Frozen Meals Across Stores

Updated Category News Views 519

Ming Tsai Launches Exciting New Frozen Meals Nationwide Ming Tsai, an acclaimed chef known for his innovative culinary skills, has recently introduced a new line of products called Mings™ frozen meals. This line aims to transport your taste buds across Asia with authentic flavors that can now be found in Walmart stores across the country. A Culinary Adventure Awaits...

Continue Reading
Truist Financial Corporation Insights on Q3 2024 Performance

Updated Category News Views 237

Truist Financial Corporation Reports Strong Q3 2024 Results Truist Financial Corporation (NYSE: TFC) released its results for the third quarter of 2024 today, showcasing its fiscal health and commitment to enhancing customer experience. The company continues to focus on delivering robust financial performance while engaging its client base and broader community. Key...

Continue Reading